Muscarinic subtypes profile modulation within a series of new antagonists, bridged bicyclic derivatives of 2,2-Diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine
摘要:
A set of new muscarinic antagonists, bridged bicyclic derivatives of 2,2-diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine (1), was synthesized and tested to evaluate their affinity and selectivity for M-1, M-2, M-3 and M-4 receptor subtypes. The conformational constraint of 1 in a bicyclic structure, and the variation in distance and stereochemistry of the active functions allowed us to modulate the selectivity of interaction with the M-1-M-3 receptor subtypes. The most interesting compound was (cis,trans)-2-(2,2-diphenylethyl)-5-methyl-tetrahydro-[1,3]dioxolo[4,5-c]pyrrole oxalate (6), which is equipotent with Pirenzepine on rabbit vas deferens (M-1-putative) but shows a better selectivity profile. (C) 2003 Elsevier Ltd. All rights reserved.
Muscarinic subtypes profile modulation within a series of new antagonists, bridged bicyclic derivatives of 2,2-Diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine
摘要:
A set of new muscarinic antagonists, bridged bicyclic derivatives of 2,2-diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine (1), was synthesized and tested to evaluate their affinity and selectivity for M-1, M-2, M-3 and M-4 receptor subtypes. The conformational constraint of 1 in a bicyclic structure, and the variation in distance and stereochemistry of the active functions allowed us to modulate the selectivity of interaction with the M-1-M-3 receptor subtypes. The most interesting compound was (cis,trans)-2-(2,2-diphenylethyl)-5-methyl-tetrahydro-[1,3]dioxolo[4,5-c]pyrrole oxalate (6), which is equipotent with Pirenzepine on rabbit vas deferens (M-1-putative) but shows a better selectivity profile. (C) 2003 Elsevier Ltd. All rights reserved.